A Phase 2 interventional study of fludarabine and rituximab in Follicular Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Terminated at 43 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-12-12.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing bortezomib in Lymphoma, Follicular — none open to participants now, none under way, none of them phase 3. Bortezomib · Lymphoma, Follicular.
Among the 36 studies testing bortezomib in Lymphoma, Follicular, this one is the 26th largest by enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2009, is one of 18 in phase 2, and was the 26th registered.
1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
Browse Lymphoma, Follicular studies →None of the 36 studies testing bortezomib in Lymphoma, Follicular is open now. The open studies under Lymphoma, Follicular, anywhere →
Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 24
First in 1999; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 48 across 1,503 interventional studies indexed under Lymphoma, Follicular.
Median enrollment 27 across the 33 interventional studies. Of the 36 that completed or were terminated, 19 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
Takeda has 8 studies filed under Lymphoma, Follicular — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 36 studies testing bortezomib in Lymphoma, Follicular, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, open-label, active-control, multicenter Phase 2 study of VELCADE+fludarabine in comparison with rituximab+fludarabine in subjects with relapsed advanced follicular lymphoma. Eligible subjects will be randomized in a 1:1 ratio between the 2 treatment arms (55 subjects per arm).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects with histological or clinical transformation to an aggressive lymphoma
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
VELCADE 1.6 mg/m2 intravenously (IV) on Days 1, 8, 15, and 22 and fludarabine 40mg/m2/day orally on Days 1 to 5 of every 35-day cycle
Drug: fludarabine · Drug: VELCADE
fludarabine 40mg/m2/day orally on Days 1 to 5 and rituximab 375mg/m2 on Day 1 of every 35-day cycle
Drug: fludarabine · Drug: rituximab
fludarabine 40mg/m2/day orally on Days 1 to 5 of every 35-day cycle
rituximab 375mg/m2 on Day 1 of every 35-day cycle
1.6 mg/m2 intravenously (IV) on Days 1, 8, 15, and 22 of every 35-day cycle
Complete Response Rate
The proportion of response-evaluable subjects who achieved a confirmed complete response (CR) or complete response unconfirmed (CRu). Disease response and progression were evaluated according to modified International Workshop Response Criteria (IWRC) criteria by radiographic imaging and other procedures as necessary.
Time frame: Up to 8 cycles (1 cycle is 35 days: 280 days)
Overall Response Rate
The proportion of subjects who achieve CR, CRu, or partial response (PR) relative to the response evaluable population. Disease response and progression were evaluated according to the modified IWRC criteria by radiographic imaging and other procedures as necessary.
Time frame: Up to 8 cycles (1 cycle is 35 days: 280 days)
| Milestone | Velcade + Fludarabine | Rituximab + Fludarabine |
|---|---|---|
| Started | 4 | 8 |
| Completed | 1 | 6 |
| Not completed | 3 | 2 |
| Withdrew: Adverse event | 3 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 |
The proportion of response-evaluable subjects who achieved a confirmed complete response (CR) or complete response unconfirmed (CRu). Disease response and progression were evaluated according to modified International Workshop Response Criteria (IWRC) criteria by radiographic imaging and other procedures as necessary.
| participants | Velcade + Fludarabine | Rituximab + Fludarabine |
|---|---|---|
| Complete Response Rate | 2 | 3 |
The proportion of subjects who achieve CR, CRu, or partial response (PR) relative to the response evaluable population. Disease response and progression were evaluated according to the modified IWRC criteria by radiographic imaging and other procedures as necessary.
| participants | Velcade + Fludarabine | Rituximab + Fludarabine |
|---|---|---|
| Overall Response Rate | 3 | 6 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Velcade + Fludarabine | — | 2/4 (50%) | 4/4 (100%) |
| Rituximab + Fludarabine | — | 2/8 (25%) | 8/8 (100%) |
| Event | Velcade + Fludarabine | Rituximab + Fludarabine |
|---|---|---|
| Abdominal painGastrointestinal disorders | 1/4 | 0/8 |
| AnaemiaBlood and lymphatic system disorders | 1/4 | 0/8 |
| Small Intestinal ObstructionGastrointestinal disorders | 1/4 | 0/8 |
| DypnoeaRespiratory, thoracic and mediastinal disorders | 0/4 | 1/8 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/4 | 1/8 |
| General physical health deteriorationGeneral disorders | 0/4 | 1/8 |
| PyrexiaGeneral disorders | 0/4 | 1/8 |
| Respiratory gas exchange disorderRespiratory, thoracic and mediastinal disorders | 0/4 | 1/8 |
| Event | Velcade + Fludarabine | Rituximab + Fludarabine |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 1/4 | 4/8 |
| ConstipationGastrointestinal disorders | 2/4 | 0/8 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/4 | 3/8 |
| AstheniaGeneral disorders | 1/4 | 3/8 |
| LeukopeniaBlood and lymphatic system disorders | 1/4 | 2/8 |
| LymphopeniaBlood and lymphatic system disorders | 0/4 | 2/8 |
| BlepharitisEye disorders | 1/4 | 0/8 |
| DiarrhoeaGastrointestinal disorders | 1/4 | 0/8 |
| Gastrointestinal painGastrointestinal disorders | 1/4 | 0/8 |
| NauseaGastrointestinal disorders | 1/4 | 1/8 |
| Age, Categorical(Participants) | Velcade + Fludarabine | Rituximab + Fludarabine | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 6 | 9 |
| >=65 years | 1 | 2 | 3 |
| Age Continuous(years) | Velcade + Fludarabine | Rituximab + Fludarabine | Total |
|---|---|---|---|
| Mean | 61.3 ± 12.84 | 60.0 ± 10.06 | 60.4 ± 10.47 |
| Sex: Female, Male(Participants) | Velcade + Fludarabine | Rituximab + Fludarabine | Total |
|---|---|---|---|
| Female | 2 | 3 | 5 |
| Male | 2 | 5 | 7 |
| Region of Enrollment(participants) | Velcade + Fludarabine | Rituximab + Fludarabine | Total |
|---|---|---|---|
| France | 0 | 3 | 3 |
| Greece | 0 | 1 | 1 |
| Spain | 1 | 0 | 1 |
| Israel | 1 | 0 | 1 |
| Germany | 0 | 1 | 1 |
| Switzerland | 1 | 0 | 1 |
| Italy | 1 | 3 | 4 |
The record gives a start of Sep 2009, a primary completion of Sep 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2012, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bortezomib
Millennium Pharmaceuticals, Inc. →